Tough At The Top: Raj Denhoy On The Drive For Growth In A Maturing Medtech Industry
The medical technology industry was a solid if tricky bet for investors in 2017, and will be so in 2018. That is the view of Jefferies Healthcare US-based equity analyst Raj Denhoy. Speaking to In Vivo during the group's London meeting in fall 2017, he gave context to the motivations and drivers of medtechs large and small for 2018 and beyond.
You may also be interested in...
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Singapore Prepares UDI System, Malaysia Seeks Regulatory Improvements And Indonesia Adjusts To Changing Environment
Medtech industry representatives from ASEANMed member economies, notably Singapore, Malaysia and Indonesia, provided regulatory updates at the February Asia Regulatory Roundtable. These roundtables are organized by the ARQon consultancy and the Asia Regulatory Professional Association (ARPA). They are sponsored by Medtech Insight.
Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.